Get the Stockscreener App
0.8212
2.24%
-0.0188
After Hours:
.82
-0.0012
-0.15%
Elutia Inc stock is traded at $0.8212, with a volume of 38,138.
It is down -2.24% in the last 24 hours and down -5.83% over the past month.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
See More
Previous Close:
$0.84
Open:
$0.852
24h Volume:
38,138
Relative Volume:
0.49
Market Cap:
$36.37M
Revenue:
$15.97M
Net Income/Loss:
$-24.40M
P/E Ratio:
-1.0827
EPS:
-0.7585
Net Cash Flow:
$-45.82M
1W Performance:
-6.68%
1M Performance:
-5.83%
6M Performance:
-30.99%
1Y Performance:
-59.14%
1-Day Range:
$0.8201
$0.8904
1-Week Range:
$0.8201
$0.9459
52-Week Range:
$0.50
$2.0869
Elutia Inc Stock (ELUT) Company Profile
Name
Elutia Inc
Sector
Industry
Phone
240-247-1143
Address
12510 PROSPERITY DRIVE, SILVER SPRING
Compare ELUT vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
0.8212 | 39.94M | 15.97M | -24.40M | -45.82M | -0.7585 |
ABT
Abbott Laboratories
|
108.33 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.17 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
303.13 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
47.80 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.90 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-02-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-02-20 | Initiated | Cowen | Outperform |
| Nov-02-20 | Initiated | Piper Sandler | Overweight |
| Nov-02-20 | Initiated | Truist | Buy |
Elutia Inc Stock (ELUT) Latest News
Elutia Inc. (NASDAQ: ELUT) Share Price, ELUT Stock News, ELUT Share Price & Updates - Kalkine
Post-surgical infections will be discussed at Elutia's upcoming talks - Stock Titan
Elutia (ELUT) Holds Steady at $0.88 as Shares Consolidate Between Support and ResistanceCall Wall - dars.gov.et
Elutia Inc. Earnings Call Highlights Funding, NXT Outlook - TipRanks
Elutia (ELUT) Move: Moves 2.32% Lower to $0.90; Price Levels: Traders Can Monitor the $0.85-$0.95 Range under the Current SnapshotSwing Entry Signals - vinanet.vn
Elutia (ELUT) Q2 2026 Earnings Call Transcript - theglobeandmail.com
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch - Sahm
Cellution Biologics Acquires SimpliDerm From Elutia for Up to $11 Million - citybiz
ELUT Looks 5.6% Overvalued on GF Value™ - GuruFocus
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc. - The Manila Times
Elutia Flat on Sale to Cellution - Baystreet.ca
Elutia sells SimpliDerm business for up to $11 million - Investing.com
Elutia sells SimpliDerm business for up to $11 million By Investing.com - Investing.com India
Elutia gets $8 million at closing as FDA clearance is expected in 2027 - Stock Titan
SILVERARC CAPITAL MANAGEMENT, LLC Trims Elutia Inc (ELUT) Stake -- Shares Look 11% Overvalued on GF Value - GuruFocus
Cellution Biologics Llc completed the acquisition of SimpliDerm human acellular dermal matrix business of Elutia Inc. for $11 million. - marketscreener.com
Elutia (ELUT) Q2 2026 Earnings: Wider-Than-Expected Loss as Shares Advance 1.49%Earnings Outlook Update - vinanet.vn
Elutia Inc (ELUT) Stock News Today - TradingKey
Elutia Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ELUT) 2026-08-16 - Seeking Alpha
Downgrade: What You Need To Know About The Latest Elutia Inc. (NASDAQ:ELUT) Forecasts - simplywall.st
Elutia secures $26M to launch NXT-41x, targetin... - Pluang
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results - Sahm
Elutia Q2 2026 slides: $26M capital raise funds NXT41x launch - Investing.com Australia
Elutia Inc. (ELUT): SilverArc Capital reports 4.9% stake in Class A shares - Stock Titan
Elutia Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic - GuruFocus
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to NXT41X Drives Strong ... By GuruFocus - Investing.com Canada
ELUT Looks 2.2% Undervalued on GF Value™ Amid Challenging Sales and Cash Flow - GuruFocus
Earnings call transcript: Elutia Q2 2026 revenue miss offset by margin gains - Investing.com Nigeria
ELUT: Q2 delivered improved margins, strong funding, and high surgeon demand for NXT-41x - TradingView
Elutia secures $26M in capital, expects FDA decision on NXT-41 - Investing.com Australia
Elutia Q2 2026 Earnings Call Transcript - Benzinga
ELUT: Improved margins, strong funding, and high surgeon demand set up NXT-41x for 2028 launch - TradingView
Elutia Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Elutia Inc. Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41X Launch in $1.5 Billion Plastic and Reconstructive Surgery Market - marketscreener.com
Elutia secures $15 million financing for product development By Investing.com - Investing.com Nigeria
Elutia Inc. (ELUT) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
Is Elutia Inc (ELUT) Positioned for Growth After Q2 Earnings? EPS at -$0.15, Revenue at $2.90M -- GF Score: 34/100 - GuruFocus
Elutia Secures $15 Million Loan Financing From Avenue Capital Group - TradingView
Elutia secures $15 million financing for product development - Investing.com
Elutia Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Elutia 2Q Sales $2.43M >ELUT - Moomoo
Elutia's Biomatrix Targets 15–20% Infection Rates in Plastic Surgery - Stock Titan
96% of Plastic Surgeons Interested in Elutia’s NXT-41x - Stock Titan
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market - marketscreener.com
Earnings To Watch: Elutia Inc (ELUT) Q2 2026 -- GF Value Sees 6% Downside - Yahoo Finance
Elutia Inc expected to post a loss of 15 cents a shareEarnings Preview - tradingview.com
Elutia Inc. (ELUT) stake of 2.19M shares reported by SilverArc - Stock Titan
Elutia Inc Stock (ELUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Elutia Inc Stock (ELUT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| NEELS GUIDO J | Director |
Jan 30 '26 |
Buy |
1.04 |
20,000 |
20,800 |
118,750 |
| NEELS GUIDO J | Director |
Jan 29 '26 |
Buy |
1.06 |
15,000 |
15,900 |
98,750 |
| NEELS GUIDO J | Director |
Jan 28 '26 |
Buy |
1.06 |
15,000 |
15,900 |
83,750 |
0.86%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):